The role of mindfulness training supported by virtual reality in the nonpharmacological treatment of schizophrenia-research design

TL;DR

This study designs a clinical trial to test if virtual reality-based mindfulness training helps people with schizophrenia more than traditional methods.

Contribution

The novel contribution is the development of a randomized controlled trial protocol for VR-based mindfulness training in schizophrenia treatment.

Findings

The trial will assess clinical outcomes, stress biomarkers, and gene expression in schizophrenia patients.

VR-MST is proposed as a scalable, nonpharmacological intervention to reduce stress and improve cognitive function.

The study design includes both objective and subjective measures across biological and cognitive domains.

Abstract

This paper presents the outcome of a clinical trial planning process developed during multicenter, multidisciplinary seminars with prospective collaborators. The study protocol, designed according to the Oxford Quality Assessment System, outlines a randomized controlled trial (RCT) evaluating a novel Virtual Reality-based Mindfulness Skills Training (VR-MST) versus standard, non-VR MST in patients with schizophrenia (SZ). The trial aims to assess the effects of VR-MST on clinical outcomes, stress-related biomarkers, and gene expression.

Eligibility criteria include: (1) SZ diagnosis based on ICD-10 and DSM-5 (2), psychotic symptom severity below 75 on the PANSS (moderately ill), and (3) age between 25 and 50 years. The protocol defines procedures for participant withdrawal and managing adverse events. The design tests both specific and general hypotheses, with pre- and post-intervention assessments in both groups, and additional pre-/post-session measurements in the VR group. Assessments span biological, symptomatic, and cognitive domains, using both objective and subjective measures.

This study may inform clinical practice by introducing a novel, engaging, evidence-based, nonpharmacological intervention. VR-MST could support stress reduction, enhance cognitive functioning, and improve daily life in SZ patients. The design is grounded in prior pilot studies, literature reviews, and clinical expertise, aiming to provide a scalable and impactful therapeutic tool.

Figures